cystic fibrosis with Pseudomonas aeruginosa infection
Respiratory · 2011–2013
5decisions
4medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tobramycin Management of a proven Pseudomonas aeruginosa infection in a patient aged 6 years or older with cystic fibrosis. | Mar 2013 | Not recommended | unclear |
| aztreonam Management of proven Pseudomonas aeruginosa infection in patients with cystic fibrosis. | Jul 2012 | Recommended with restriction | no section in document |
| aztreonam Management of proven Pseudomonas aeruginosa infection in patients with cystic fibrosis. | 2012 | Recommended with restriction | no section in document |
| tobramycin, solution for inhalation Management of proven Pseudomonas aeruginosa infection in a patient with cystic fibrosis. | Mar 2011 | Recommended with restriction | unclear |
| colistimethate sodium Treatment of colonisation and infections of the lung due to susceptible Pseudomonas aeruginosa in patients with cystic fibrosis. | Mar 2011 | Noted | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.